Table of contents


On 27 May 2005, orphan designation (EU/3/05/283) was granted by the European Commission to Amgen Europe BV, The Netherlands, for recombinant megakariopoiesis stimulating protein for the treatment of idiopathic thrombocytopenic purpura.

Recombinant megakariopoiesis stimulating protein has been authorised in the EU as Nplate since 4 February 2009.

Key facts

Active substance
Recombinant megakaryopoiesis-stimulating protein
Medicine name
Disease / condition
Treatment of idiopathic thrombocytopenic purpura
Date of decision
Orphan decision number

Sponsor's contact details

Amgen Europe BV
Minervum 7061
NL 4817 ZK Breda
The Netherlands
Telephone: +31 12 23 43 61 57
Telefax: +31 12 23 42 68 14

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating